Employing GEMMs of BCC, Sánchez-Danés and coworkers showed that the combination of vismodegib treatment with Lgr5 lineage ablation, or an inhibitor of Wnt signaling, led to tumor eradication, demonstrating that the synergy between Wnt and Smoothened inhibitors is a clinically feasible strategy to overcome tumor recurrence in BCC [160]. The gene discussed is LGR5; the disease is skin basal cell carcinoma.